Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
3.330
+0.010 (0.30%)
At close: Dec 5, 2025, 4:00 PM EST
3.300
-0.030 (-0.90%)
After-hours: Dec 5, 2025, 7:58 PM EST
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$303,800
Profits / Employee
-$1,076,972
Market Cap
770.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GOSS News
- 11 days ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 2 months ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 2 months ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 3 months ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 3 months ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire